Enovis Co. (NYSE:ENOV) Stock Holdings Lifted by Kennedy Capital Management LLC

Kennedy Capital Management LLC raised its position in shares of Enovis Co. (NYSE:ENOV) by 5.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 158,557 shares of the company’s stock after purchasing an additional 8,743 shares during the period. Kennedy Capital Management LLC owned 0.28% of Enovis worth $6,957,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Aster Capital Management DIFC Ltd bought a new stake in Enovis in the fourth quarter worth $29,000. Quadrant Capital Group LLC lifted its position in shares of Enovis by 53.0% in the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company’s stock worth $30,000 after buying an additional 239 shares during the last quarter. UMB Bank n.a. boosted its stake in shares of Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after acquiring an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. increased its holdings in shares of Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after acquiring an additional 300 shares during the last quarter. Finally, FMR LLC raised its stake in shares of Enovis by 20.5% in the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after acquiring an additional 484 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Stock Down 0.5 %

ENOV stock opened at $31.93 on Friday. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of -14.58 and a beta of 1.86. The company has a 50-day moving average of $38.85 and a two-hundred day moving average of $42.55. Enovis Co. has a 52-week low of $29.32 and a 52-week high of $59.63. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.

Enovis (NYSE:ENOV) last announced its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. As a group, equities research analysts anticipate that Enovis Co. will post 2.79 EPS for the current year.

Analyst Ratings Changes

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 target price on shares of Enovis in a research report on Wednesday.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.